Key Takeaways
A new FDA panel signals momentum toward updated HRT guidance
Dr. Cathleen Brown described a recent FDA panel discussion where medical experts, including an orthopedic surgeon, advocated for revisiting the black box warnings that have shaped HRT prescribing since the Women's Health Initiative study — a sign, she said, that broader access to HRT may be on the horizon.
Weighing breast cancer risk means looking at the full health picture
Many women fear that HRT will cause breast cancer. Dr. Brown and Dr. Green noted that for most women without a genetic predisposition like BRCA, the modest risk increase is best understood alongside HRT's cardiovascular and longevity benefits — the point isn't that one benefit outweighs the risk, but that the decision should be in weighing overall health rather than fear of a single outcome.
DHEA is a gentler path to testosterone than pellets
Dr. Green explained that testosterone pellets can cause a cycle of early euphoria followed by side effects as levels build up, and come with a four-month commitment with no way to reverse course. DHEA, by contrast, is dosed low enough to nudge testosterone into a normal female range without those risks.
Full transparency about medications and supplements is essential for safety
Dr. Brown emphasized that patients should disclose every medication, vitamin, and supplement they take — not just prescriptions — since seemingly harmless additions can still interact with HRT.
Vulvar tissue changes aren't always reversible with estrogen alone
Dr. Brown and Dr. Green noted that significant tissue changes, like clitoral retraction, may not respond to topical estrogen if the anatomy has already changed — and that conditions like lichen sclerosis, which can look similar, require an in-person exam and a different treatment entirely.
